Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ASTRAZENECA

AZN.LGB0009895292London SEGBGBP
Stock price
ASTRAZENECA
Loading chart...

Coverage

Latest articles

AstraZeneca's Baxdrostat offers new hope for resistant hypertension
7 Oct 2025, 06:02AZN.LLondon SE

AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.

AstraZeneca, Daiichi Sankyo drug improves survival in aggressive breast cancer trial
6 Oct 2025, 06:30AZN.LLondon SE

AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.

AstraZeneca drug bests standard in key breast cancer trial
29 Sept 2025, 06:31AZN.LLondon SE

AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.

AstraZeneca seeks deeper U.S. investor base with NYSE listing
29 Sept 2025, 06:03AZN.LLondon SE

AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.

AstraZeneca drug wins EU backing after recent trial setbacks
22 Sept 2025, 06:07AZN.LLondon SE

AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.

AstraZeneca drug wins EU backing after a recent setback
22 Sept 2025, 06:03AZN.LLondon SE

AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Enhertu improved PFS in HER2-low and ultralow29 Apr 2024
Truqap recommended for EU breast cancer approval29 Apr 2024
1st Quarter Results25 Apr 2024
AstraZeneca increases 2024 dividend by 7% 11 Apr 2024
Result of AGM11 Apr 2024
Enhertu approved in US for HER2+ solid tumours8 Apr 2024
Imfinzi improved OS & PFS in limited-stage SCLC5 Apr 2024
FDA accepts Dato-DXd BLA for breast cancer2 Apr 2024
Voydeya approved in US2 Apr 2024
Total Voting Rights2 Apr 2024
Ultomiris approved in the US for NMOSD 25 Mar 2024
AstraZeneca to acquire Fusion19 Mar 2024
  • Previous
  • 1
  • More pages
  • 12
Search
Company
ASTRAZENECA
AZN.LLondon SE
Website: Unavailable
Coverage
16
  • 3
  • Next
  • 13
  • 14
  • More pages
  • 17
  • Next
  • Filings
    204